HSIC — Henry Schein, Inc.

Summary of Henry Schein's Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Global Sales: $3.4 billion, up 7.7% year-over-year (5.8% constant currency growth).
• GAAP Operating Margin: 4.76%, down 10 basis points from the previous year.
• Non-GAAP Operating Margin: 7.42%, flat year-over-year despite lower gross margins.
• GAAP Net Income: $101 million ($0.85 per diluted share), compared to $94 million ($0.74 per diluted share) in Q4 2024.
• Non-GAAP Net Income: $160 million ($1.34 per diluted share), up from $149 million ($1.19 per diluted share) year-over-year.
• Adjusted EBITDA: $291 million, an 8.4% increase from Q4 2024.
• Operating Cash Flow: $381 million, significantly up from $204 million in Q4 2024.
• Share Repurchases: Approximately 2.8 million shares repurchased at an average price of $71.10.

2. Strategic Updates and Business Highlights

• Leadership Transition: Fred Lowery will officially take over as CEO next week, succeeding Stanley Bergman, who remains Chairman.
• BOLD+1 Strategic Plan: Non-GAAP operating income from high-growth, high-margin businesses is nearing 50% of total operating income, with a goal to exceed 50% by 2027.
• E-commerce Platform: Rollout of henryschein.com is underway, with completion expected for U.S. dental and Canadian customers in Q1 2026.
• Innovative Product Launches: Introduction of Vvardis' Curodont for early-stage caries and partnership with Amazon Web Services for AI integration.
• Market Performance: Strong growth in global dental equipment sales, particularly in the U.S., with double-digit growth in traditional equipment.

3. Forward Guidance and Outlook

• 2026 Sales Growth: Expected to be in the range of 3% to 5% over 2025.
• Non-GAAP EPS Guidance: Projected between $5.23 and $5.37, reflecting growth of 5% to 8% compared to 2025.
• Adjusted EBITDA Growth: Anticipated mid-single-digit growth compared to 2025.
• Value Creation Initiatives: Expected to deliver over $200 million in operating income improvement over the next few years, with a run rate of $125 million by the end of 2026.

4. Bad News, Challenges, or Points of Concern

• Operating Margin Pressure: Margins are impacted by product mix dynamics, particularly with lower-margin value implants growing faster than premium options.
• Respiratory Product Demand: Lower demand for respiratory products is expected to continue into Q1 2026, affecting the medical segment.
• Market Stability: While the U.S. dental market shows positive trends, international markets are mixed, and overall growth in the U.S. implant market is below historical averages.
• Restructuring Costs: Ongoing restructuring costs related to value creation initiatives may impact short-term profitability.

5. Notable Q&A Insights

• Market Durability: Stanley Bergman indicated that the dental market is stable with positive sentiment among dentists, suggesting a favorable environment for investment in technology.
• Value Creation Initiatives: The benefits from operational improvements are expected to be more heavily weighted towards the second half of 2026, with some initial costs in the first half.
• Pricing Dynamics: There are no significant pricing pressures noted in the specialty products segment, with stable pricing in the premium implant category.
• Tariff Mitigation: The company plans to pass on any tariff increases to customers and is actively sourcing from alternative countries to mitigate impacts.

Overall, Henry Schein reported solid financial results for Q4 2025, with positive growth across various segments and strategic initiatives in place to drive future performance, despite facing some challenges in specific product categories and market dynamics.